



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 12, 2018

Clarissa Desjardins  
President and Chief Executive Officer  
Clementia Pharmaceuticals Inc.  
4150 Sainte-Catherine Street West, Suite 550  
Montreal, Quebec, Canada H3Z 2Y5

**Re: Clementia Pharmaceuticals Inc.**  
**Registration Statement on Form F-1**  
**Filed October 5, 2018**  
**File No. 333-227726**

Dear Ms. Desjardins:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at 202-551-5019 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Martin C. Glass, Esq.